These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36230681)

  • 1. Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
    Jiménez N; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domenech M; Figols M; González-Billalabeitia E; Jiménez Peralta D; Rodríguez-Carunchio L; García-Esteve S; Garcia de Herreros M; Ribal MJ; Prat A; Mellado B
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Jiménez N; Garcia de Herreros M; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; García-Esteve S; Rodríguez-Carunchio L; Trias I; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domènech M; Figols M; Carles J; Suárez C; Herrero Rivera D; González-Billalabeitia E; Cívico C; Sala-González N; Ruiz de Porras V; Ribal MJ; Prat A; Mellado B
    Eur Urol Oncol; 2024 Aug; 7(4):954-964. PubMed ID: 38429210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
    Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
    Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
    Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole blood
    Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
    Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer.
    Lee D; Lim B; Nguyen TT; Choi SY
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice.
    Lendorf ME; Petersen PM; Svendsen AS; Lindberg H; Brasso K
    Eur Urol Open Sci; 2021 Feb; 24():25-33. PubMed ID: 34337492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.
    Velez MG; Kosiorek HE; Egan JB; McNatty AL; Riaz IB; Hwang SR; Stewart GA; Ho TH; Moore CN; Singh P; Sharpsten RK; Costello BA; Bryce AH
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):479-483. PubMed ID: 34294873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of
    Soerohardjo I; Widodo I; Heriyanto DS; Zulfiqqar A; Anwar SL
    Ann Med Surg (Lond); 2020 Dec; 60():549-554. PubMed ID: 33299560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
    Conteduca V; Di Tullio P; Allamprese R; Bruno G; Lolli C; Schepisi G; Rosano A; Giordano G; Garofoli M; Chiuri VE; Fratino L; Zanardi E; Galli L; Massari F; Falagario U; Rescigno P; Fornarini G; Sanguedolce F; Santini D; Procopio G; Caffo O; Carrieri G; Landriscina M; De Giorgi U
    Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
    Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
    BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).
    Sentana-Lledo D; Chu X; Jarrard DF; Carducci MA; DiPaola RS; Wagner LI; Cella D; Sweeney CJ; Morgans AK
    Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38688766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.